12:05:42 EDT Tue 28 Mar 2023
Enter Symbol
or Name

Login ID:
Resverlogix Corp
Symbol RVX
Shares Issued 243,788,665
Close 2022-04-19 C$ 0.44
Recent Sedar Documents

Resverlogix extends $6M (U.S.) debenture by one year

2022-04-19 17:18 ET - News Release

Mr. Donald McCaffrey reports


Resverlogix Corp. has closed a one-year extension of the company's $6.0-million (U.S.) 10-per-cent secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co. Ltd. (Hepalink), and payment of accrued interest thereon, extending the maturity date to May 13, 2023.

"We are extremely pleased that our partner Hepalink has extended the debenture's maturity date. This speaks volumes to the ongoing supportive and collaborative partnership we have with Hepalink, and our common goal of bringing lifesaving therapies to highly unmet medical needs," stated Donald McCaffrey, president and chief executive officer of Resverlogix.

About Apabetalone

Apabetalone (RVX-208) is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes.

Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes while maintaining a well-described safety profile -- leading to a new way to treat chronic disease. Apabetalone received breakthrough therapy designation from the United States Food and Drug Administration (FDA) and is the only drug of its class with an established safety record in human clinical trials, with well over 4,200 patient years on drug across 10 clinical trials.


Following a publication in Nature, authored by a consortium of top universities and research institutions, on March 23, 2020, Resverlogix launched a COVID-19 program, conducting research internally and enlisting world-renowned collaborators. Studies -- published in prestigious scientific journals (including Cell) -- demonstrate that apabetalone has the potential to act against COVID-19 with a unique dual mechanism: first by preventing viruses from entering the cells and replicating; and second by averting excessive inflammatory reactions that can cause severe and lasting organ damage.

A phase 2b clinical trial is evaluating apabetalone in combination with standard of care for patients hospitalized with COVID-19. The investigational treatment could potentially reduce the severity and duration of COVID-19. Apabetalone's unique dual mechanism also means that it has the potential to show efficacy against new COVID-19 variants and may even help fight other viruses.

Resverlogix has partnered with Eversana, the pioneer of next-generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for COVID-19 in Canada and the United States. Eversana is currently leading clinical outreach and advocacy for apabetalone in the Canadian market.


In February, 2020, apabetalone became the first therapy of its kind to receive breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) -- for a major cardiovascular indication -- following the groundbreaking findings from the BETonMACE phase 3 study. Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have Type 2 diabetes mellitus.

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. The company aims to improve patients' lives by restoring biological functions altered by serious illnesses such as cardiovascular disease back to a healthier state.

The company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.

We seek Safe Harbor.

© 2023 Canjex Publishing Ltd. All rights reserved.